Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Loss Per Share (Tables)

Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2022

Schedule of Reconciliation of Numerator and Denominator for Basic and Diluted Loss Per Share

Presented in the table below is a reconciliation of the numerator and denominator for the basic and diluted loss per share calculations for the three months ended March 31, 2022 and 2021:

	2022			2021
	March 31,
	2022			2021
Net loss from continuing operations	$	(4,406	)	$	(7,358	)
Net loss from discontinuing operations		(4,757	)		(8	)
Net loss	$	(9,163	)	$	(7,366	)
Basic and diluted weighted average shares outstanding		29,012,536			3,184,106
Basic and diluted net loss per share:
Continuing operations	$	(0.15	)	$	(2.31	)
Discontinuing operations		(0.17	)		-
Net loss	$	(0.32	)	$	(2.31	)

Schedule of Computation of Diluted Shares Outstanding

The following securities were not included in the computation of diluted shares outstanding for the for the three months ended March 31, 2022 and 2021 because the effect would be anti-dilutive:

	2022		2021
	March 31,
	2022		2021
Common stock warrants		2,292,996		2,301,576
Common stock options		2,766,616		2,268,543
Total		5,059,612		4,570,119